Med. Pro Praxi 2007; 5: 211-216

Chronické srdeční selhání

doc. MUDr. Petr Heinc Ph.D
I. interní klinika FN a LF UP Olomouc

Chronické srdeční selhání je závažné onemocnění s velmi špatnou prognózou v okamžiku stanovení diagnózy. Článek se zabývá patofyziologií, neurohumorálními mechanizmy a diagnostikou chronického srdečního selhání s následným rozborem účinné farmakoterapie a podstatou i indikacemi resynchronizační léčby v případě selhání farmakoterapie.

Keywords: chronické srdeční selhání, patofyziologické mechanizmy, farmakologická léčba, resynchronizační léčba

Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heinc P. Chronické srdeční selhání. Med. praxi. 2007;4(5):211-216.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. CIBIS II Investigators a Comittees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999; 353: 9-13. Go to original source...
    2. Cleland JG, Gemmell I, Khand A et al. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-241. Go to original source... Go to PubMed...
    3. Cleland JG, Oakley CM. Vascular tone in heart failure: the neuroendocrine-therapeutic interface. Br Heart J 1991; 66: 264-267. Go to original source... Go to PubMed...
    4. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463. Go to original source... Go to PubMed...
    5. Cody RJ, Haas GJ, Binkley PF et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504. Go to original source... Go to PubMed...
    6. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: A concensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569. Go to original source... Go to PubMed...
    7. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997; 80: 15L-25L. Go to original source... Go to PubMed...
    8. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patient with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353. Go to original source... Go to PubMed...
    9. Daubert CJ, Ritter P, LeBreton H et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. PACE 1998; 21: 239-245. Go to original source... Go to PubMed...
    10. Francis GS, Benedict C, Johnstone DE et al. For the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82: 1724-1729. Go to original source... Go to PubMed...
    11. Goldstein S, Fagerberg B, Hjalmarson A et al. Metoprolol controlled release/extended release in patient with severe heart failure: analysis of the experience in the MERIT- HF study. J Am Coll Cardiol 2001; 38: 932-938. Go to original source... Go to PubMed...
    12. Kautzner J, Bytešník J, Čihák R, Málek I. Biventrikulární stimulace u nemocných se srdečním selháním, učební křivka. Cor Vasa 2001; 43 (Suppl): 36-37.
    13. Lerman A, Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular left-ventricular dysfunction. Lancet 1993; 341: 1105-1109. Go to original source... Go to PubMed...
    14. Lupínek P, Málek I, Frídl P et al.: Prediktory prognózy u nemocných s chronickým srdečním selháním vyšetřovaných s úvahou o transplantaci srdce. Cor Vasa 2002; 44(Suppl.abstrakta): 70-71.
    15. Mc Murray JJ, Petrie MC, Murdoch DR et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19(Suppl P): P9-16.
    16. McMurray J, Swedberg K, Hogg K. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004; 43: 317-327. Go to original source... Go to PubMed...
    17. Murdoch DR, Love MP, Robb SD et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. Eur Heart J 1998;19:1829-1835. Go to original source... Go to PubMed...
    18. Nelson GS, Curry CW, Wyman BT et al. Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. Circulation 2000; 101: 2703-2709. Go to original source... Go to PubMed...
    19. Pitt B, Poole-Wilson PA, Segal R et al. On behalf of ELITE II investigators. Effect of Losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trialthe Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587. Go to original source... Go to PubMed...
    20. Pitt B, Zannad F, Remme WJ et al. For the RALES Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 1999; 341: 709-717. Go to original source... Go to PubMed...
    21. Rao VU, Spinale FG. Controlling myocardial matrix remodeling: implications for heart failure. Cardiol Rev 1999; 7: 136-143. Go to original source... Go to PubMed...
    22. Sogaard P, Egeblad H, Kim UVY et al. Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy. J Am Coll Cardiol 2002; 40: 723-730. Go to original source... Go to PubMed...
    23. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140. Go to original source... Go to PubMed...
    24. Špinar J., Hradec J., Meluzín J. et al. Doporučení pro diagnostiku a léčbu srdečního selhání ČKS 2006. Cor et Vasa 2007; 49 (1): K 5-33.
    25. Táborský M, Kautzner J, Bytešník J et al. Zásady pro implantace kardiostimulátorů a implantabilních kardioverterů-defibrilátorů a srdeční resynchronizační léčbu. Cor Vasa 2005; 47 (9): 59-68.
    26. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
    27. The MERIT HF Study Group: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart failure (MERIT-HF). Mortality study. Lancet 1999; 353: 2001-2007. Go to original source...
    28. Victor F, Leclerq C, Mabo P et al. Optimal right ventricular pacing site in chronically implanted patients: a prospective randomized crossover comparison of apical and outflow tract pacing. J Am Coll Cardiol 1999; 33: 511-516. Go to original source... Go to PubMed...
    29. Widimský J, Balažovjech I, Filipovský J et al. Effect of perindopril in congestive heart failure. PRESI-a multicentre Czech and Slovak study. Cor Vasa 1999; 41: 368-376.
    30. Widimský J, Jerie P, Kremer HJ et al. Czech and Slovak Spirapril Intervention Study (CASSIS). A randomized, placebo and active-controlled, double blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol 1995; 48: 95-102. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.